Adiponectin and insulin resistance are related to restenosis and overall new PCI in subjects with normal glucose tolerance: the prospective AIRE Study

[1]  D. Gallo,et al.  Prasugrel or ticagrelor in patients with acute coronary syndrome and diabetes: a propensity matched substudy of RENAMI , 2018, European heart journal. Acute cardiovascular care.

[2]  Claudio Aguayo,et al.  Association between insulin resistance and the development of cardiovascular disease , 2018, Cardiovascular Diabetology.

[3]  M. Barbieri,et al.  Inflammatory Cytokines and SIRT1 Levels in Subcutaneous Abdominal Fat: Relationship With Cardiac Performance in Overweight Pre-diabetics Patients , 2018, Front. Physiol..

[4]  G. Engström,et al.  Comparing the inflammatory profiles for incidence of diabetes mellitus and cardiovascular diseases: a prospective study exploring the ‘common soil’ hypothesis , 2018, Cardiovascular Diabetology.

[5]  Z. Zeng,et al.  Adiponectin as a potential therapeutic target for the treatment of restenosis. , 2018, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[6]  G. Paolisso,et al.  Non‐ST‐elevation myocardial infarction outcomes in patients with type 2 diabetes with non‐obstructive coronary artery stenosis: Effects of incretin treatment , 2018, Diabetes, obesity & metabolism.

[7]  K. Node,et al.  Effect of pioglitazone on cardiometabolic profiles and safety in patients with type 2 diabetes undergoing percutaneous coronary artery intervention: a prospective, multicenter, randomized trial , 2018, Heart and vessels.

[8]  R. Rubinshtein,et al.  Impact of diabetes and early revascularization on the need for late and repeat procedures , 2018, Cardiovascular Diabetology.

[9]  G. Paolisso,et al.  Effects of incretin treatment on cardiovascular outcomes in diabetic STEMI-patients with culprit obstructive and multivessel non obstructive-coronary-stenosis , 2018, Diabetology & Metabolic Syndrome.

[10]  G. Bruno,et al.  NTproBNP in insulin-resistance mediated conditions: overweight/obesity, metabolic syndrome and diabetes. The population-based Casale Monferrato Study , 2017, Cardiovascular Diabetology.

[11]  J. Egido,et al.  Regulation of visceral and epicardial adipose tissue for preventing cardiovascular injuries associated to obesity and diabetes , 2017, Cardiovascular Diabetology.

[12]  Y. Sakai,et al.  Insulin Resistance as a Predictor of the Late Catch-up Phenomenon After Drug-Eluting Stent Implantation. , 2016, Circulation journal : official journal of the Japanese Circulation Society.

[13]  G. Reaven,et al.  Insulin resistance: The linchpin between prediabetes and cardiovascular disease , 2016, Diabetes & vascular disease research.

[14]  Li Wang,et al.  Influence of insulin resistance on in-stent restenosis in patients undergoing coronary drug-eluting stent implantation after long-term angiographic follow-up , 2015, Coronary artery disease.

[15]  Yen-Lin Chen,et al.  Identification of insulin resistance in subjects with normal glucose tolerance. , 2014, Annals of the Academy of Medicine, Singapore.

[16]  G. Reaven.  Insulin resistance and coronary heart disease in nondiabetic individuals. , 2012, Arteriosclerosis, thrombosis, and vascular biology.

[17]  Ruiyan Zhang,et al.  Insulin resistance predicts progression of de novo atherosclerotic plaques in patients with coronary heart disease: a one-year follow-up study , 2012, Cardiovascular Diabetology.

[18]  S. Miura,et al.  Determination of the cut-off plasma adiponectin level associated with a lower risk of restenosis in patients with stable angina , 2011, Coronary artery disease.

[19]  S. Moreira,et al.  Noninvasive method to estimate anaerobic threshold in individuals with type 2 diabetes , 2011, Diabetology & metabolic syndrome.

[20]  O. Baysan,et al.  Is low adiponectin levels more sensitive predictor of in-stent restenosis: new questions and challenges. , 2010, International journal of cardiology.

[21]  A. Newman,et al.  The burden of cardiovascular disease in the elderly: morbidity, mortality, and costs. , 2009, Clinics in geriatric medicine.

[22]  M. Erbil,et al.  Adiponectin levels in patients undergoing coronary stenting. , 2009, Clinical biochemistry.

[23]  Y. Jang,et al.  Plasma adiponectin and resistin levels as predictors of mortality in patients with acute myocardial infarction: data from infarction prognosis study registry , 2009, Coronary artery disease.

[24]  P. Presbitero,et al.  Admission glycemia and markers of inflammation are independent outcome predictors in primary PCI in non-diabetic patients. , 2008, Minerva cardioangiologica.

[25]  K. Piestrzeniewicz,et al.  Value of blood adipose tissue hormones concentration--adiponectin, resistin and leptin in the prediction of major adverse cardiac events (MACE) in 1-year follow-up after primary percutaneous coronary intervention in ST-segment elevation acute myocardial infarction. , 2008, Neuro endocrinology letters.

[26]  J. Bełtowski,et al.  Adiponectin and its role in cardiovascular diseases. , 2008, Cardiovascular & hematological disorders drug targets.

[27]  J. Gumprecht,et al.  Effect of blood glucose levels on prognosis in acute myocardial infarction in patients with and without diabetes, undergoing percutaneous coronary intervention. , 2008, Cardiology journal.

[28]  G. Stasik-Pres,et al.  Relationship between blood glucose on admission and prognosis in patients with acute myocardial infarction treated with percutaneous coronary intervention. , 2007, Kardiologia polska.

[29]  J. Tune,et al.  Adipokines and Coronary Vasomotor Dysfunction , 2007, Experimental biology and medicine.

[30]  H. Park,et al.  Serum resistin as a biological marker for coronary artery disease and restenosis in type 2 diabetic patients. , 2007, Circulation journal : official journal of the Japanese Circulation Society.

[31]  Mitsuo Matsuda,et al.  Relationship of serum adiponectin level to adverse cardiovascular events in patients who undergo percutaneous coronary intervention. , 2007, Circulation journal : official journal of the Japanese Circulation Society.

[32]  E. Barrett-Connor,et al.  Association of adiponectin with coronary heart disease and mortality: the Rancho Bernardo study. , 2006, American journal of epidemiology.

[33]  W. März,et al.  Adiponectin and mortality in patients undergoing coronary angiography. , 2006, The Journal of clinical endocrinology and metabolism.

[34]  G. Beck,et al.  Adiponectin and mortality in patients with chronic kidney disease. , 2006, Journal of the American Society of Nephrology : JASN.

[35]  S. Yaturu,et al.  Resistin and adiponectin levels in subjects with coronary artery disease and type 2 diabetes. , 2006, Cytokine.

[36]  André Luiz Colaço,et al.  Citocinas, disfunção endotelial e resistência à insulina , 2006 .

[37]  Jong Chun Park,et al.  The Effect of Insulin Resistance on Prognosis of Non-Diabetic Patients Who Underwent Percutaneous Coronary Intervention , 2006, Journal of Korean medical science.

[38]  Jan Frystyk,et al.  Plasma Adiponectin, Body Mass Index, and Mortality in Patients With Chronic Heart Failure , 2005, Circulation.

[39]  G. Hansson.  Inflammation, atherosclerosis, and coronary artery disease. , 2005, The New England journal of medicine.

[40]  E. Ford,et al.  Is nondiabetic hyperglycemia a risk factor for cardiovascular disease? A meta-analysis of prospective studies. , 2004, Archives of internal medicine.

[41]  Roberto Torella,et al.  Glucose metabolism and coronary heart disease in patients with normal glucose tolerance. , 2004, JAMA.

[42]  Cynthia J. Girman,et al.  Plasma adiponectin levels and risk of myocardial infarction in men. , 2004, JAMA.

[43]  R. Turner,et al.  Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man , 1985, Diabetologia.

[44]  C. Di Mario,et al.  Association of Insulin Resistance, Hyperleptinemia, and Impaired Nitric Oxide Release With In-Stent Restenosis in Patients Undergoing Coronary Stenting , 2003, Circulation.

[45]  B. Horne,et al.  Effect of fasting glucose levels on mortality rate in patients with and without diabetes mellitus and coronary artery disease undergoing percutaneous coronary intervention. , 2003, American heart journal.

[46]  T. Akasaka,et al.  Impact of insulin resistance on neointimal tissue proliferation after coronary stent implantation. Intravascular ultrasound studies. , 2002, Journal of diabetes and its complications.

[47]  David O. Williams,et al.  ACC/AHA Guidelines for Percutaneous Coronary Intervention (Revision of the 1993 PTCA Guidelines)—Executive Summary , 2001 .

[48]  E J Topol,et al.  Coronary morphologic and clinical determinants of procedural outcome with angioplasty for multivessel coronary disease. Implications for patient selection. Multivessel Angioplasty Prognosis Study Group. , 1990, Circulation.

[49]  T. Ryan.  Guidelines for percutaneous transluminal coronary angioplasty. A report of the American College of Cardiology/American Heart Association Task Force on Assessment of Diagnostic and Therapeutic Cardiovascular Procedures (Subcommittee on Percutaneous Transluminal Coronary Angioplasty). , 1988, Journal of the American College of Cardiology.